Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Mesoblast Limited
  6. Company
    MSB   AU000000MSB8

MESOBLAST LIMITED

(MSB)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Mesoblast Limited is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The Company is using its mesenchymal lineage cell technology platform to develop and commercialize allogeneic cellular medicines to treat complex inflammatory diseases. Its product candidate includes Remestemcel-L ((RYONCIL) for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD), Rexlemestrocel-L (REVASCOR) for the advanced chronic heart failure (CHF) and MPC-06-ID for the treatment of chronic low back pain caused by disc degeneration (CLBP). Its product candidate MPC-150-IM for the treatment or prevention of chronic heart failure and MPC-25-IC for the treatment or prevention of acute myocardial infarction. Its product candidate also includes MPC-300-IV for the treatment of biologic-refractory rheumatoid arthritis and diabetic nephropathy.

Number of employees : 83 people.
Sales per Business
20202021Delta
Adult Stem Cell Technology47.16100%9.97100% -78.87%
AUD in Million
Sales per region
20202021Delta
Australia, United States and Singapore47.16100%9.97100% -78.87%
AUD in Million
Managers
Name Title Age Since
Silviu Itescu, Dr. Chief Executive Officer, MD & Executive Director 63 2011
Andrew Chaponnel Chief Financial Officer & Head-Finance - 2021
Fred Grossman, Dr. Chief Medical Officer - 2019
Dagmar Rosa-Bjorkeson Chief Operating Officer 56 2020
Michael Robert Spooner Independent Non-Executive Director - 2012
Donal Paul O'Dwyer Independent Non-Executive Director 67 2004
Eric A. Rose, Dr. Independent Non-Executive Director 69 2013
William Matt Burns Independent Non-Executive Vice Chairman 74 -
Joseph Swedish Independent Non-Executive Chairman 68 2019
Shawn Cline Tomasello Independent Non-Executive Director 61 2018
Members of the board
Name Title Age Since
Joseph Swedish Independent Non-Executive Chairman 68 2019
Michael Robert Spooner Independent Non-Executive Director - 2012
Donal Paul O'Dwyer Independent Non-Executive Director 67 2004
Silviu Itescu, Dr. Chief Executive Officer, MD & Executive Director 63 2011
Eric A. Rose, Dr. Independent Non-Executive Director 69 2013
William Matt Burns Independent Non-Executive Vice Chairman 74 -
Shawn Cline Tomasello Independent Non-Executive Director 61 2018
Philip James Facchina Independent Non-Executive Director 58 2021
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 647,924,087 555,805,448 85.8% 0 0.0% 85.8%
Shareholders
NameEquities%
Silviu Itescu 68,958,928 10.6%
M&G Investment Management Ltd. 51,752,865 7.98%
Thorney Investment Group Australia Pty Ltd. 24,696,000 3.81%
The Vanguard Group, Inc. 14,538,579 2.24%
Vanguard Investments Australia Ltd. 8,494,082 1.31%
Independent Asset Management Pty Ltd. 7,870,558 1.21%
BlackRock Fund Advisors 6,874,495 1.06%
JPMorgan Asset Management (UK) Ltd. 6,629,931 1.02%
Novum Asset Management AG 6,193,000 0.95%
Norges Bank Investment Management 5,168,662 0.80%
Company contact information
Mesoblast Ltd.
55 Collins Street
Level 38
Melbourne, Victoria (VIC) 3000

Phone : +61.3.9639.6036
Fax : +61.3.9639.6030
Web : http://www.mesoblast.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Mesoblast Limited
Sector Other Biotechnology & Medical Research